UNSPSC 51401562: Chlordiazepoxide lactam

This classification denotes a benzodiazepine with the molecular formula C15H11ClN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8X1XP5M0SB, chemically known as 5-phenyl-7-chloro-3h-1,4-benzodiazepin-2(1h)-one 4-oxide, but more generally known as chlordiazepoxide lactam, which bears US NIH Compound Identifier 13756. European Medicines Agency schedules chlordiazepoxide lactam or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06179MIG.

Most nations, for tariff purposes, schedule chlordiazepoxide lactam under HS 29339110. SMILES: C1CCC(CC1)C2=[N+](CC(=O)NC3C2CC(CC3)CL)[O-].

UNSPSC 51401562 Chlordiazepoxide lactam is a Commodity-tier code that shows minimal alignment between its nominal pharmaceutical designation and the actual state and local procurement activity currently tagged to it. The recent opportunities listed under this code involve naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are chlordiazepoxide lactam specifically. State and local governments do procure controlled substances and pharmaceuticals through formal solicitations, but the opportunities surfaced here appear to reflect broader pharmaceutical supply and community health initiatives rather than targeted procurement of this specific benzodiazepine compound. The issuing bodies include a Florida county health department (Seminole County), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). The code shows no evidence of sustained, category-wide activity tied to chlordiazepoxide lactam as a distinct product line.

Geographically, recent activity spans Florida, Texas, Minnesota, and Oregon (through MMCAP membership), but the scope mismatch limits the utility of these signals for vendors targeting this specific commodity. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries to its community health building. The Texas HHS Commission released an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription contracting capabilities, designed to inform future formal procurement strategy. MMCAP issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, requiring NDC-coded product submissions and cGMP and DSCSA compliance, with contract terms beginning July 1, 2026. The code as tagged shows little relevant recent activity for chlordiazepoxide lactam procurement specifically; bidders should verify actual commodity demand through direct outreach to issuing bodies rather than relying on this code's categorization.